This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed ADCETRIS click here.

ADCETRIS significantly improved PFS in patients at increased risk of relapse post-ASCT1-3

With a median observation time of 30 months:1

  • ADCETRIS significantly improved PFS per IRF (n=165) versus placebo (n=164) in HL patients at high risk of relapse post-ASCT:
    • ADCETRIS significantly improved PFS by 18.8 months versus placebo
    • Median PFS of 42.9 months (95% CI: 30.4–42.9) versus 24.1 months (95% CI: 11.5–not estimable) [hazard ratio=0.57;] (95% CI: 0.40–0.81; p=0.001)

PFS by independent review
PFS by independent review

Adapted from Moskowitz CH, et al. 2015

Sustained PFS benefit vs placebo at 4 years2

PFS by investigator assessment (4-year update)
PFS by investigator assessment

Adapted from Moskowitz CH, et al. 2016

  • 4-year follow up PFS per investigator remains 20% higher in ADCETRIS arm versus the placebo arm (HR= 0.52)
  • Interim analysis of OS did not show a significant difference between treatment arms: [Hazard Ratio=1.15 (p=0.6204)] (95% CI: 0.67-1.97)
    • 84% of patients who required subsequent therapy were treated with ADCETRIS.
    • Assessment of OS is ongoing, but no OS data were included in the 4-year update

Study details

Patients with more risk factors had the greatest PFS benefit with ADCETRIS consolidation treatment2

The results of these post-hoc analyses suggest increased benefit for patients with two or more risk factors but no difference based on any of the individual risk factors.

Study details

PFS per investigator sub-group analysis:
≥2 risk factors (4-year update)2*
PFS per investigator sub-group analysis

Adapted from Moskowitz CH, et al. 2016

ADCETRIS has a generally manageable toxicity profile. PN generally resolves or improves in most patients1,2

  • Patients received a median of 15 cycles of therapy in each arm
    • PN was the most common AE
    • Most patients showed resolution or improvement of symptoms at 30 month follow up
  • Symptoms of PN continued to improve or resolve during extended follow up
  • QoL maintained with ADCETRIS therapy versus placebo4
ADCETRIS has a generally manageable toxicity profile1,2
ADCETRIS
group (n=167)
Placebo
group (n=160)
Any Grade ≥Grade3* Any Grade ≥Grade 3
Any event 163 (98%) 93 (56%) 142 (89%) 51 (32%)
Peripheral sensory neuropathy 94 (56%) 17 (10%) 25 (16%) 2 (1%)
Neutropenia 58 (35%) 49 (29%) 19 (12%) 16 (10%)
Upper respiratory tract infection 44 (26%) 0 37 (23%) 2 (1%)
Fatigue 40 (24%) 3 (2%) 29 (18%) 4 (3%)
Peripheral motor neuropathy 38 (22%) 10 (6%) 3 (2%) 1 (1%)
Nausea 36 (22%) 5 (3%) 12 (8%) 0
Cough 35 (21%) 0 26 (16%) 0
Diarrhoea 33 (20%) 3 (2%) 16 (10%) 1 (1%)

*Treament-emergent adverse events (TEAEs) with an incidence of 20% or more in the brentuximab vedotin group

Scotland
Not funded. Available via IPTR/private funding
Northern Ireland
Not funded. Available via IFR/private funding
England
Not funded. Available via IFR/private funding
Wales
Not funded. Available via IFT/private funding

Consolidation with brentuximab vedotin in R/R HL patients at high risk of relapse post-ASCT

Dr Graham Collins

Oxford University Hospitals NHS Trust, Oxford, UK


Clinical opinion

How would you identify a patient with high risk Hodgkin lymphoma?

Which risk factor is more important?

View case study

Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.

Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com.